Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Research

Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer

Jie Du1, Shuanying Yang1*, Xiuli Lin1, Lina Bu2, Yandong Nan1, Shufen Huo1 and Wenli Shang1

Author affiliations

1 Department of Respiratory Medicine, Second Affiliated Hospital of Medical School, Xi'an Jiaotong University, N-710000 Xi'an, China

2 Medical Department of Second Hospital of Xi'an, N-710000 Xi'an, China

For all author emails, please log on.

Citation and License

Diagnostic Pathology 2010, 5:60  doi:10.1186/1746-1596-5-60

Published: 20 September 2010

Abstract

Background

The purpose of this study is to discover potential biomarkers in serum for the detection of small cell lung cancer (SCLC).

Methods

74 serum samples including 30 from SCLC patients and 44 from healthy controls were analyzed using ClinProt system combined with matrix-assisted laser desorption/ionization time-of-flight masss spectrometry (MALDI-TOF-MS). ClinProt software and genetic algorithm analysis selected a panel of serum markers that most efficiently predicted which patients had SCLC.

Results

The diagnostic pattern combined with 5 potential biomarkers could differentiate SCLC patients from healthy persons, with a sensitivity of 90%, specificity of 97.73%. Remarkably, 88.89% of stage I/II patients were accurately assigned to SCLC.

Conclusions

Anchorchip-time-of-flight spectrometry technology will provide a highly accurate approach for discovering new biomarkers for the detection of SCLC.